RayKnowChina Research Map
Shortlist0

RecruitingNasopharyngeal carcinomaPhase 3

Registered title, quoted from ClinicalTrials.gov

PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC

An open trial on nasopharyngeal carcinoma, registered on ClinicalTrials.gov. Led by Sun Yat-sen University Cancer Center; 4 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 5

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Sun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
  2. Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
  3. Study siteGuangxi Medical University Cancer Hospital广西医科大学附属肿瘤医院NanningHospital page
  4. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  5. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07235319, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 9

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (9 points)Hide the checklist
  1. 18 years to 70 years; sex: all

    Registered eligibility fields

  2. Histologically confirmed differentiated non-keratinizing carcinoma or undifferentiated non-keratinizing carcinoma by tissue biopsy, with radiologically detectable metastatic lesions. Pathological confirmation of metastatic lesions is recommended but not mandatory.

    Inclusion criterion 2

  3. Stage IV NPC according to the 9th edition of the UICC/AJCC staging system.

    Inclusion criterion 4

  4. Achieved complete response (CR) or partial response (PR) after 4-6 cycles of chemotherapy plus PD-1 inhibitor therapy.

    Inclusion criterion 8

    Prior treatment with PD-1/PD-L1 or CTLA-4 inhibitors.

    Exclusion criterion 2

  5. ECOG performance status 0-1.

    Inclusion criterion 3

  6. INR or PT ≤ 1.5 × ULN, unless on therapeutic anticoagulation and values within therapeutic range,aPTT ≤ 1.5 × ULN, unless on therapeutic anticoagulation and values within therapeutic range

    Inclusion criterion 10

  7. At least one measurable lesion per RECIST v1.1.

    Inclusion criterion 7

  8. History of other malignancies within the past 5 years, except adequately treated basal cell carcinoma, squamous cell skin cancer, or in-situ cervical cancer.

    Exclusion criterion 4

    Hepatitis B: HBsAg positive with peripheral blood HBV DNA ≥ 1000 copies/mL

    Exclusion criterion 7

    Hepatitis C: HCV antibody positive, eligible only if HCV RNA is negative

    Exclusion criterion 8

    HIV infection

    Exclusion criterion 9

  9. Pregnant or breastfeeding women, or those planning pregnancy during the study period.

    Exclusion criterion 13

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07235319, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age 18-70 years, any gender.
  • Histologically confirmed differentiated non-keratinizing carcinoma or undifferentiated non-keratinizing carcinoma by tissue biopsy, with radiologically detectable metastatic lesions. Pathological confirmation of metastatic lesions is recommended but not mandatory.
  • ECOG performance status 0-1.
  • Stage IV NPC according to the 9th edition of the UICC/AJCC staging system.
  • No prior anti-tumor treatment for NPC (radiotherapy, chemotherapy, surgery, etc.).
  • Expected survival ≥ 3 months.
  • At least one measurable lesion per RECIST v1.1.
  • Achieved complete response (CR) or partial response (PR) after 4-6 cycles of chemotherapy plus PD-1 inhibitor therapy.
  • Adequate organ function within 14 days before first dose, defined as:

Hematology:Hemoglobin ≥ 90 g/L,ANC ≥ 1.5 × 10⁹/L,Platelet count ≥ 100 × 10⁹/L Renal Function:Creatinine ≤ 1.5 × ULN, or creatinine clearance (CrCl) / eGFR ≥ 60 mL/min Liver Function:Total bilirubin ≤ 1.5 × ULN,AST and ALT ≤ 2.5 × ULN, or ≤ 5 × ULN in the presence of liver metastases

  • INR or PT ≤ 1.5 × ULN, unless on therapeutic anticoagulation and values within therapeutic range,aPTT ≤ 1.5 × ULN, unless on therapeutic anticoagulation and values within therapeutic range

Exclusion Criteria:

  • Prior anti-tumor therapy for nasopharyngeal carcinoma, including radiotherapy, chemotherapy, surgery, or immunotherapy.
  • Prior treatment with PD-1/PD-L1 or CTLA-4 inhibitors.
  • Presence of uncontrolled or symptomatic central nervous system (CNS) metastases.
  • History of other malignancies within the past 5 years, except adequately treated basal cell carcinoma, squamous cell skin cancer, or in-situ cervical cancer.
  • Active autoimmune disease or history of autoimmune disease requiring systemic treatment (e.g., corticosteroids, immunosuppressants) within the past 2 years, except for stable hypothyroidism, type 1 diabetes mellitus, or resolved childhood asthma/atopy.
  • Known history of active pulmonary tuberculosis (TB). Suspected active TB must be excluded by chest X-ray, sputum examination, and assessment of clinical signs and symptoms.
  • Hepatitis B: HBsAg positive with peripheral blood HBV DNA ≥ 1000 copies/mL
  • Hepatitis C: HCV antibody positive, eligible only if HCV RNA is negative
  • HIV infection
  • Clinically significant cardiovascular disease (e.g., uncontrolled hypertension, unstable angina, myocardial infarction within 6 months, congestive heart failure ≥ NYHA class II, or serious arrhythmia).
  • Interstitial lung disease, non-infectious pneumonitis, or history of ≥ grade 2 pneumonitis.
  • Major surgery within 4 weeks before enrollment, or unhealed surgical wound.
  • Pregnant or breastfeeding women, or those planning pregnancy during the study period.
  • Known allergy or hypersensitivity to study drugs or their excipients.
  • Any condition that, in the investigator's judgment, would interfere with trial participation or interpretation of results.

Quoted from ClinicalTrials.gov, NCT07235319, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07235319, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07235319